June 20 (Reuters) - Jazz Pharmaceuticals' ( JAZZ )

experimental drug to treat a neurological condition that causes

involuntary and rhythmic shaking failed to reduce tremor

severity in a mid-stage study, the company said on Thursday.

Shares of Jazz fell as much as 4% in premarket trading.

While improvements were observed in patients who were

treated with the drug, suvecaltamide, these were not

statistically significant, the company said.

The drug also failed to show statistically significant

improvement in symptom severity, the secondary goal of the

study.

Suvecaltamide, however, was well tolerated with safety

consistent with previous studies, Jazz said, adding that one

participant experienced a treatment-related serious adverse

event. Jazz said it will further evaluate data from the study.

In the trial which enrolled 420 patients with essential

tremor, a 30 milligram dosage of suvecaltamide failed to reduce

severity of tremors after 12 weeks of treatment.

It is testing the drug in a separate study as a potential

treatment for Parkinson's disease-related tremors.

Jazz said it expects data from the Parkinson's disease

tremor trial in the first quarter of 2025.